Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

Michael J. Morris, MD
Published: Saturday, Feb 18, 2017



Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

In a phase I/IIa clinical trial, the effects of radium-223 with docetaxel (Taxotere) versus docetaxel alone on bone biomarkers was found that the patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

According to Morris, these bone biomarkers are important because they are one of the most closely associated tests to survival.
 


Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

In a phase I/IIa clinical trial, the effects of radium-223 with docetaxel (Taxotere) versus docetaxel alone on bone biomarkers was found that the patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

According to Morris, these bone biomarkers are important because they are one of the most closely associated tests to survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x